Alpha-fetoprotein peptide–HLA class I histocompatibility antigen, A-2 alpha chain complex (AFP peptide–HLA-A*02:01 complex)

The **Alpha-fetoprotein peptide–HLA-A*02:01 complex** is a molecular structure formed when a peptide fragment derived from alpha-fetoprotein (AFP)—a fetal and tumor-associated antigen—is presented on the cell surface by the HLA-A*02:01 class I major histocompatibility complex molecule. This complex is recognized by cytotoxic T lymphocytes, mediating an immune response primarily against tumor cells, particularly in hepatocellular carcinoma in HLA-A*02:01-positive individuals[5]. Such complexes are targets for peptide-based cancer immunotherapies and have roles in tumor immune surveillance and immunodiagnostics. Structural studies show that the peptide is bound in the antigen-binding cleft of HLA-A*02:01, where it is available for T cell receptor engagement, triggering antigen-specific T cell immunity[1][3][4][5].

Other names

AFP peptide–HLA-A*02:01 complexAlpha-fetoprotein–HLA-A2 complexAFP/HLA-A2 complexAFP peptide/human leukocyte antigen A*02:01 complex

Induction of cytotoxic T lymphocyte responses against tumor cells expressing AFP in the context of HLA-A*02:01[5]. Immune checkpoint inhibitors may indirectly enhance recognition via this complex[3][4].